SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 - PubMed (original) (raw)
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7
Gareth J Inman et al. Mol Pharmacol. 2002 Jul.
Abstract
Small molecule inhibitors have proven extremely useful for investigating signal transduction pathways and have the potential for development into therapeutics for inhibiting signal transduction pathways whose activities contribute to human diseases. Transforming growth factor beta (TGF-beta) is a member of a large family of pleiotropic cytokines that are involved in many biological processes, including growth control, differentiation, migration, cell survival, adhesion, and specification of developmental fate, in both normal and diseased states. TGF-beta superfamily members signal through a receptor complex comprising a type II and type I receptor, both serine/threonine kinases. Here, we characterize a small molecule inhibitor (SB-431542) that was identified as an inhibitor of activin receptor-like kinase (ALK)5 (the TGF-beta type I receptor). We demonstrate that it inhibits ALK5 and also the activin type I receptor ALK4 and the nodal type I receptor ALK7, which are very highly related to ALK5 in their kinase domains. It has no effect on the other, more divergent ALK family members that recognize bone morphogenetic proteins (BMPs). Consistent with this, we demonstrate that SB-431542 is a selective inhibitor of endogenous activin and TGF-beta signaling but has no effect on BMP signaling. To demonstrate the specificity of SB-431542, we tested its effect on several other signal transduction pathways whose activities depend on the concerted activation of multiple kinases. SB-431542 has no effect on components of the ERK, JNK, or p38 MAP kinase pathways or on components of the signaling pathways activated in response to serum.
Similar articles
- SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S, Major C, Laping NJ, Roberts AB. DaCosta Byfield S, et al. Mol Pharmacol. 2004 Mar;65(3):744-52. doi: 10.1124/mol.65.3.744. Mol Pharmacol. 2004. PMID: 14978253 - Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S, Klein C, Roh J, Kaivo-Oja N, Mottershead DG, Korchynskyi O, Ritvos O, Hsueh AJ. Mazerbourg S, et al. Mol Endocrinol. 2004 Mar;18(3):653-65. doi: 10.1210/me.2003-0393. Epub 2003 Dec 18. Mol Endocrinol. 2004. PMID: 14684852 - The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T. Tojo M, et al. Cancer Sci. 2005 Nov;96(11):791-800. doi: 10.1111/j.1349-7006.2005.00103.x. Cancer Sci. 2005. PMID: 16271073 Free PMC article. - Bone morphogenetic proteins.
Chen D, Zhao M, Mundy GR. Chen D, et al. Growth Factors. 2004 Dec;22(4):233-41. doi: 10.1080/08977190412331279890. Growth Factors. 2004. PMID: 15621726 Review. - Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Tsuchida K, et al. Endocr J. 2008 Mar;55(1):11-21. doi: 10.1507/endocrj.kr-110. Epub 2007 Sep 14. Endocr J. 2008. PMID: 17878607 Review.
Cited by
- Inhibition of transforming growth factor β (TGF-β) signaling can substitute for Oct4 protein in reprogramming and maintain pluripotency.
Tan F, Qian C, Tang K, Abd-Allah SM, Jing N. Tan F, et al. J Biol Chem. 2015 Feb 13;290(7):4500-11. doi: 10.1074/jbc.M114.609016. Epub 2014 Dec 29. J Biol Chem. 2015. PMID: 25548277 Free PMC article. - TGFβ biology in cancer progression and immunotherapy.
Derynck R, Turley SJ, Akhurst RJ. Derynck R, et al. Nat Rev Clin Oncol. 2021 Jan;18(1):9-34. doi: 10.1038/s41571-020-0403-1. Epub 2020 Jul 24. Nat Rev Clin Oncol. 2021. PMID: 32710082 Free PMC article. Review. - Autocrine TGFβ1 Opposes Exogenous TGFβ1-Induced Cell Migration and Growth Arrest through Sustainment of a Feed-Forward Loop Involving MEK-ERK Signaling.
Ungefroren H, Christl J, Eiden C, Wellner UF, Lehnert H, Marquardt JU. Ungefroren H, et al. Cancers (Basel). 2021 Mar 17;13(6):1357. doi: 10.3390/cancers13061357. Cancers (Basel). 2021. PMID: 33802809 Free PMC article. - Suppressive Role of ACVR1/ALK2 in Basal and TGFβ1-Induced Cell Migration in Pancreatic Ductal Adenocarcinoma Cells and Identification of a Self-Perpetuating Autoregulatory Loop Involving the Small GTPase RAC1b.
Ungefroren H, Braun R, Lapshyna O, Konukiewitz B, Wellner UF, Lehnert H, Marquardt JU. Ungefroren H, et al. Biomedicines. 2022 Oct 20;10(10):2640. doi: 10.3390/biomedicines10102640. Biomedicines. 2022. PMID: 36289908 Free PMC article. - Modeling the Control of TGF-β/Smad Nuclear Accumulation by the Hippo Pathway Effectors, Taz/Yap.
Labibi B, Bashkurov M, Wrana JL, Attisano L. Labibi B, et al. iScience. 2020 Aug 21;23(8):101416. doi: 10.1016/j.isci.2020.101416. Epub 2020 Jul 29. iScience. 2020. PMID: 32798968 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous